Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples